The estimated Net Worth of Nicholas Augustinos is at least $14.5 Milion dollars as of 15 December 2023. Mr. Augustinos owns over 3,976 units of Dexcom Inc stock worth over $2,330,719 and over the last 15 years he sold DXCM stock worth over $11,799,360. In addition, he makes $324,596 as Independent Director at Dexcom Inc.
Nicholas has made over 16 trades of the Dexcom Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 3,976 units of DXCM stock worth $489,128 on 15 December 2023.
The largest trade he's ever made was selling 97,541 units of Dexcom Inc stock on 9 December 2013 worth over $3,281,279. On average, Nicholas trades about 4,339 units every 111 days since 2009. As of 15 December 2023 he still owns at least 34,040 units of Dexcom Inc stock.
You can see the complete history of Mr. Augustinos stock trades at the bottom of the page.
Nicholas Augustinos serves as Independent Director of the Company. He has served on our Board since November 2009. From December 2015 through December 2018, Mr. Augustinos served as President and CEO of Aver, Inc., a company specializing in bundled payment, analytics and payment solutions. He has served on the Board of Directors of Aver since September 2014, and was Chairman of the Board of Aver during 2019. From November 2011 until December 2015, Mr. Augustinos worked for Cardinal Health, Inc. as its Senior Vice President for Health Information Services and Strategy. From March 2005 through October 2011, Mr. Augustinos worked for Cisco Systems, Inc. (“Cisco”), a networking company. At Cisco, he held various positions, including Director of Cisco’s Internet Business Solutions Group, Senior Director, Global Healthcare Solutions Group, and Senior Director of Global Healthcare Operations. In January 2015, Mr. Augustinos was appointed to the Board of Directors of the California Health Care Foundation (“CHCF”), which seeks to improve care for all Californians through innovations that improve quality, increase efficiency, and lower the cost of care. Prior to CHCF, he served on the Board of Directors of the SCAN Foundation, an organization dedicated to advancing the development of a sustainable continuum of quality care for seniors, from June 2011 until December 2014. Mr. Augustinos served on the Board of Directors of Audax Health, now Rally, from March 2012 until February 2014. With a 35-year career in healthcare and healthcare technology, Mr. Augustinos has broad managerial, consulting and business development experience in the private and public sectors.
As the Independent Director of Dexcom Inc, the total compensation of Nicholas Augustinos at Dexcom Inc is $324,596. There are 12 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.
Nicholas Augustinos is 61, he's been the Independent Director of Dexcom Inc since 2009. There are 9 older and 19 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
Nicholas's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Over the last 19 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff a Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: